Earle A. Chiles Research Institute

Introducing Providence St. Joseph Health Digital Commons

Providence St. Joseph Health (PSJH) recently launched a new platform to highlight the scholarly activities of its providers, researchers and caregivers: Digital Commons. The institutional repository serves as a singular...

New immunotherapy options for liver cancer

Checkpoint inhibitors are showing promise as a potential new line of treatment for people with liver cancer. The Earle A. Chiles Research Institute at Providence Cancer Institute currently has six studies open to liver...

CAR T-cell trial offers promising second-line therapy for B-cell lymphoma

Patients who have relapsed or failed first-line treatment for aggressive forms of B-cell non-Hodgkin lymphoma may qualify to receive a promising CAR T-cell therapy in a new clinical trial at Providence Cancer Institute.

The 11th floor of our Robert W. Franz Cancer Center at Providence Portland Medical Center is now open and blessed!

The 11th floor of our Robert W. Franz Cancer Center at Providence Portland Medical Center is now open and blessed! This new space allows us to expand and consolidate our outpatient cancer services in the new Providence...

Nobel Prize Honors Immunotherapy Researchers; Work Included Clinical Trials Led by Providence Dr. Walter Urba

The announcement that the Nobel Prize in Medicine has been awarded to two cancer immunotherapy researchers is a significant acknowledgement of the effect of immunotherapy and the work that has been done by the Providence...

PARP-inhibitor study opens for BRCA+, HER2- breast cancer

PARP inhibitors are emerging as “one of the promising breakthroughs in experimental oncology,” and have the potential to offer significant benefits for women with BRCA-mutant breast cancers.

Providence Cancer Institute Franz Clinic offers expanded outpatient services

From groundbreaking research to innovative treatments to compassionate care, everything we do at Providence Cancer Institute is for you, our patients. That's why we have expanded and consolidated outpatient cancer services...

Providence remembers Elsie Franz Finley

PROVIDENCE CANCER INSTITUTE – It is with deep sadness we announce the passing of Elsie Franz Finley who died Aug. 14, 2018. She was 97 years old.

Clinical trials offer new options for advanced bladder/urothelial cancers

Recent research has opened up new treatment options for advanced bladder cancer and other urothelial cancers, and clinical trials are contributing to the growing knowledge of how checkpoint inhibitors and other...

Phase 1 trials advance promising new immunotherapies for cancer

Phase 1 studies are the springboard for advancing new cancer treatments. The Earle A. Chiles Research Institute, a division of Providence Cancer Institute in the Robert W. Franz Cancer Center, is often able to offer...

Providence and Agonox Researchers Publish Groundbreaking Tumor Killing T-cell Research

Researchers at the Earle A. Chiles Research Institute, or EACRI, and Agonox, Inc. have published groundbreaking work concerning tumor-killing T cells which could greatly improve the immune response in cancer patients...

Adoptive T-cell therapy – the “Advance of the Year” – offered at Providence in clinical trials for lymphoma, melanoma, lung, head and neck cancers

Providence Cancer Institute is one of the few specialized centers in the world offering clinical trials of adoptive T-cell immunotherapy

Bountiful Treatment Options Offer Optimism for Lung Cancer

Cancer Survivor Inspires 'Creating Hope' Donors; Event Breaks Record to Support Providence Research and Treatment

In a powerful speech to a packed house, Becky Roth spoke emotionally about the cancer that changed, but didn’t claim, her life. And, despite losing two leg bones used for her jaw reconstruction – and against...

First-in-human study targets advanced lung cancer

For people with advanced lung cancer, clinical trials open up new treatment options and offer access to promising new therapies. At Providence Cancer Institute, 19 studies of novel lung cancer therapies are open to...

One study, multiple immunotherapy combinations for hormone-receptor-positive, HER2-negative breast cancer

Women with metastatic hormone-receptor-positive, HER2-negative breast cancer who have progressed after treatment with a CDK4/6 inhibitor may qualify for a newly opened immunotherapy study at Providence Cancer Institute.

New immunotherapy studies for people with advanced melanoma

More than 10 studies of investigational and FDA-approved immunotherapies for people with advanced melanoma are currently open at Providence Cancer Institute.

Transoral robotic surgery yields benefits for Providence throat cancer patients

A recent assessment of the first 170 throat-cancer patients treated with transoral robotic surgery followed by risk-adapted adjuvant therapy at Providence Cancer Institute offers compelling evidence in favor of this new...

Providence opens groundbreaking immunoradiotherapy clinical trial for patients with newly diagnosed head and neck cancer

Many clinical trials are open only to patients with metastatic disease. One of the translational research goals of the Providence Head and Neck Cancer Program is to bring immunotherapy into treatment earlier.

Adoptive T-cell transfer study opens for head and neck cancer patients

Adoptive T-cell transfer therapy is emerging as one of the most effective treatments to date for people with advanced melanoma. Now this treatment is available to patients with advanced or recurrent head and neck cancers...

Oregonians Benefit From Providence Philanthropists

It was a year in the record books for Providence Foundations of Oregon in 2017. They raised more than $50 million - and received the single largest gift ever - marking the most successful fundraising year in the 35 year...

New apalutamide study opens for prostate cancer

A new phase 3 study at Providence Cancer Institute will compare the effectiveness of three different treatment regimens in men with biochemically recurrent prostate cancer.

Immunotherapy study opens for patients with triple negative breast cancer

The study will compare the safety and effectiveness of pembrolizumab plus chemotherapy, versus chemotherapy alone, to determine whether the combination improves outcomes for patients with triple negative breast cancer.

The Earle A. Chiles Research Institute Shines at SITC 2017 Annual Meeting

Walter J. Urba, M.D., Ph.D., Member, director and endowed chair, Earle A. Chiles Research Institute, Providence Cancer Institute The Earle A. Chiles Research Institute, a division of Providence Cancer Institute at the...

Providence Honors Early Advocate of Immunotherapy for Lifetime of Generosity and Service

In his lifetime and through his estate, the late Robert W. Franz gave close to $40 million to Providence Portland Medical Foundation. Providence Cancer Institute has been renamed in his honor.

Phase I research at Providence Cancer Institute

Phase I studies are the foundation for advancing cancer treatment with new agents and combinations of therapies. Providence Cancer Institute is often able to offer patients first-in-human clinical trials of novel cancer...

Promising one-of-a-kind clinical trial adds immunotherapy to colorectal cancer treatment protocol

A first-of-its-kind clinical study may offer new hope to patients battling rectal cancer. The Phase 2 study, newly underway at Providence Cancer Institute, is led by Kristina Young, M.D., Ph.D., who was recognized in 2016...

60 Minutes Australia features Patient 71, Julie Randall, and Providence Cancer Institute

With the release of her book Patient 71, Australia native Julie Randall has given cancer patients across the globe hope for life after cancer. Her remarkable story of overcoming stage IV metastatic melanoma was featured in...

Julie Randall shares about life after cancer at Providence Creating Hope Dinner

Known as "Patient 71," persistence paid off for Australian cancer patient Julie Randall Learn more about her story › She now devotes her time to sharing her inspirational story and spreading a word of hope to...

Members of the Earle A. Chiles Research Institute Garner Spotlight of ASCO and National Media

The Earle A. Chiles Research Institute, a division of Providence Cancer Center in Portland, Ore., was well-represented at the 2017 annual meeting of the American Society of Clinical Oncology held June 2-6 in Chicago, Ill.

National Cancer Institute scientist joins Providence, honored nationally for unique and promising Immunotherapy research

It has been a busy and exciting start to 2017 for immunotherapy researcher Eric Tran, Ph.D., and it could make a great difference in the lives of people fighting cancer.

Targeted therapy and immunotherapy studies for people with lung cancer

More than 20 studies of promising new therapies for lung cancer patients are open now at Providence Cancer Center, including studies of targeted therapies and novel immunotherapy combinations.

Combination Immunotherapy with Galectin-3 Inhibitor GR-MD-02 Enhances Effects in Pre-clinical Models and Early Results of Phase 1 Clinical Trials

First-in-human data presented at GTCBio 9th Immunotherapeutics & Immunomonitoring Conference NORCROSS, Ga. (February 7, 2017) – Galectin Therapeutics Inc. (NASDAQ: GALT), the...

Immunotherapy for Breast Cancer

Immunotherapy is a treatment approach that harnesses the immune system to recognize, attack and eliminate cancer. The opportunity to conduct immunotherapy research for breast cancer patients is what drew medical oncologist...

Phase I Research at Providence Cancer Center

Patients with a variety of cancer types are eligible to receive new and promising treatments when they participate in Phase I research studies at Providence Cancer Center.

Melanoma Research

Providence physicians and scientists have been leading the way in melanoma research and treatment for more than 20 years. Our findings have resulted in new ways to boost immune response, which has improved the standard of...

Oral, head and neck cancer research at Providence Cancer Center

Providence Oral, Head and Neck Cancer Clinic offers world-class care for patients with benign and malignant tumors of the oral cavity (mouth), tongue, pharynx (throat), larynx (voice box), nose, paranasal sinuses, salivary...

Gastrointestinal cancer research at Providence Cancer Center

Providence Cancer Center is actively involved in gastrointestinal cancer research, focusing our attention on cancers of the upper (esophagus and stomach), middle (pancreas, liver, gall bladder, bile ducts and small...

NIH awards two grants to Drs. Crittenden and Gough

The National Institutes of Health has awarded two significant grants to Providence Cancer Center researchers

New hope for cancer patients; Providence joins international research network formed by Bristol-Myers Squibb

An unprecedented international collaboration promises to take cancer treatment research to a new level and allow substantially more patients at Providence Cancer Center to take part in clinical trials every year.

Remembering Robert W. Franz

Robert W. Franz, a supporter of cancer research at Providence and philanthropic leader here for more than 30 years, passed away Aug. 9 at Providence Portland Medical Center.

Lung Cancer Research at Providence Cancer Center

The Providence Thoracic Oncology Program emphasizes a multidisciplinary approach to cancer management. Our clinical trials program offers a broad array of innovative clinical research, including studies of new surgical...

Vice President Biden ties Providence to Cancer Moonshot

More than 150 people took part as Providence Cancer Center participated in Vice President Biden’s Cancer Moonshot Summit. The goal is to make a decade worth of advances toward a cure in five years, from increasing...

Major Providence supporter Earle M. Chiles passes away

We mourn the passing of Earle M. Chiles, 83, a long-time champion and supporter of providing exceptional health care for Providence patients in Oregon.

Nearly One Million Dollars Raised for Immunotherapy Research at Providence

Excited by the promise and power of immunotherapy research, Providence Cancer Center supporters raised nearly $1 million in the month of May, with most of that coming at the 2016 Creating Hope through Innovation Dinner May...

Providence cancer physician and scientist named as one of nation's 15 most promising young researchers

Just a year into her career as a Providence Cancer Center radiation oncologist and scientist, Kristina Young, M.D., Ph.D., has been recognized as one of 15 most promising young researchers in the nation by the Sidney...

Immunoregulartory Protein (Cancer)

Providence Cancer Center researchers might have identified how to determine if a patient with advanced melanoma will likely respond to a certain immunotherapy treatment.

Breakthrough lung cancer drug helps clinical trial patient

A breakthrough drug for treating the most common type of lung cancer was just approved by the Food and Drug Administration ahead of schedule following two successful clinical trials, including one that involved patients at...